ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

DIGEN Co., Ltd. offers audio-visual technology and active overseas marketing through technology, know-how and challenging investment on research and development. Founded in 1999, they have developed Wide Screen Monitor and Universal TV Tuner settop box compatible with NTSC/PAL/ SECAM for the first time in Korea and mini size monitor in the range of 2.5 inches and 4 inches and automotive TFT LCD TV/Monitor from 5 inches and 8 inches. And with 6.4 inches VGA monitor they secure enough technology for Digital Display field.

STERIS, Inc., a subsidiary of STERIS Plc (Ireland), is a company headquartered in the United States specializing in orthopedic, prosthetic, and surgical appliances and supplies.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany.

GPC Biotech is a German biopharmaceutical company that discovers and develops anticancer drugs. The company’s product portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer. In March 2000, the company acquired Mitotix, Inc., an American drug discovery and development company focused on treatments for cancer and fungal infections. GPC Biotech was founded in 1997 and currently operates as a subsidiary of Agennix AG.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

American Sterilizer Co., a subsidiary of STERIS Plc (Ireland), is a company headquartered in Pittsburgh, PA, that manufactures sterilization equipment.

LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France.

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

They have provided general information for the allergy sufferer and healthcare professionals about the prevention, diagnosis and treatment of the allergic condition with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy), the only treatment to deal with the underlying cause and not just the symptoms!

Qingdao Yabo Biotechnology Co., Ltd., established on 2011-03-30, Business scope includes crude heparin sodium and crude chondroitin sulfate(non edible,non-medicinal),API(chorionic gonadotropin)processing,wholesale,retail:API(crude urogonadotropin),Agricultural technology research and development,vegetable,fruit acquisition,sorting,Sales,Warehousing Services(Does not contain national prohibited items and flammable and explosive items,Freezing,refrigeration,Refrigeration and Hazardous Chemical Storage),Import and export of goods and technology(Projects prohibited by national laws and regulations shall not be operated,Laws and regulations restrict operations before obtaining a license to operate).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Green + Joint Stock Corp. engages in the manufacture and distribution of pharmaceutical and herbal products. The company was founded in 2016 and is headquartered in Ben Tre, Vietnam.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

NIPPI is a manufacturing company that develops aircraft components, target systems, rocket components, space equipment, and aircraft repair.

Provides fully integrated contract manufacturing services to medical device manufacturers worldwide in the cardiovascular, endoscopy and orthopedic markets